All In Biotech

Drug Trial Radar · NCT05403749

A Study of Longer Interval of IVT IBI302 in Subjects With nAMD

A Multi-center, Randomized, Double-masked, Active-controlled Study to Evaluate the Longer Interval of Intravitreal (IVT) Injection of IBI302 in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Last checked: Nov 19, 2026Latest source record: Jun 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 132 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

132

Actual

Start

Jun 29, 2022

Primary completion

May 13, 2024

Study completion May 13, 2024

Sponsor

Sponsor type
Industry
First posted
Jun 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed for multi-center, randomized, double-masked, active-controlled study to evaluate the longer interval of intravitreal injection of IBI302 in subjects with neovascular age-related macular degeneration.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

  • dose 1 IBI302Biological

    After 4 loading monthly intravitreal injections of dose 1 IBI302,the following IBI302 IVT is given as descript in protocol.

  • AfliberceptDrug

    Three consecutive monthly intravitreal injections of 2.0mg Aflibercept followed by injection every other month

  • dose 2 IBI302Biological

    After 4 loading monthly intravitreal injections of dose 2 IBI302,the following IBI302 IVT is given as descript in protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of BCVA from baselineTime frame: Baseline to week 40

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai First People's Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.